InsiderSignalSign in
← Insider buys

SVRA

Savara Inc. · Healthcare

Insiders sold $2.4M of Savara Inc. in the last 12 months and bought none

$0Bought, 12 mo
$2.4MSold, 12 mo
$914.3MMarket cap
Follow SVRA

SVRA over the last year

No insider buys filed in this year

SVRA after insider buys

3 months after each buy, from the first price a copier could get.

+9.4%Average
+5.4 ptsVs S&P 500
7 of 10Higher

10 buys since 2017 with 3 months of prices.

Every filing

56 insider filings since 2017, newest first

SVRASell

David L Lowrance · Chief Financial Officer

$2.2M−42.4%Jun 23
SVRASell

David A Ramsay · Director

$121K−1.0%Dec 19
SVRABuy

Richard J Hawkins · Director

$99K+72.0%Jun 23
SVRABuy

David A Ramsay · Director

$416K+6.0%Apr 1
SVRABuy

Joseph S Mccracken · Director

$59K+10.0%Nov 20
SVRABuy

David A Ramsay · Director

$288K+4.0%Nov 18
SVRASell

Matthew Pauls · CEO

$396K−6.0%Dec 29
SVRASell

David L Lowrance · CFO

$47K−3.0%Dec 29
SVRASell

Nevan C Elam · Director

$442K−81.0%Dec 29
SVRABuy

Ali Behbahani · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Rick Yang · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Paul Edward Walker · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Scott D Sandell · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Edward T Mathers · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Mohamad Makhzoumi · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Anthony A. Florence Jr. · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Carmen Chang · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Forest Baskett · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

Growth Equity Opportunities 17, LLC · 10% owner

$1.0M+1.0%Jul 19
SVRABuy

David A Ramsay · Director

$56K+2.0%Jan 3
SVRABuy

David A Ramsay · Director

$82K+3.0%Dec 20
SVRABuy

David A Ramsay · Director

$187K+8.0%Sep 27
SVRABuy

David A Ramsay · Director

$45K+2.0%Sep 8
SVRABuy

David A Ramsay · Director

$142K+6.0%Sep 1
SVRABuy

David A Ramsay · Director

$27K+2.0%Dec 2
SVRABuy

David A Ramsay · Director

$27K+2.0%Dec 1
SVRABuy

David A Ramsay · Director

$215K+18.0%Nov 22
SVRABuy

David A Ramsay · Director

$176K+14.0%Sep 30
SVRABuy

David A Ramsay · Director

$115K+11.0%Aug 19
SVRABuy

Matthew Pauls · CEO

$32K+8.0%Aug 18
SVRASell

Badrul A. Chowdhury · Chief Medical Officer

$78K−25.0%May 17
SVRABuy

Matthew Pauls · CEO

$50K+10.0%Apr 19
SVRABuy

Matthew Pauls · CEO

$50K+9.0%Mar 22
SVRABuy

Joseph S Mccracken · Director

$100K+69.0%Mar 15
SVRABuy

David A Ramsay · Director

$1.0M+565.0%Mar 15
SVRABuy

Matthew Pauls · CEO

$50K+13.0%Feb 23
SVRABuy

David A Ramsay · Director

$95K+171.0%Jun 19
SVRASell

Richard J Hawkins · Director

$278K−100.0%May 16
SVRASell

David L Lowrance · CFO

$81K−100.0%May 3
SVRASell

David L Lowrance · CFO

$68K−100.0%Apr 8
SVRASell

Jaakko Taneli Jouhikainen · President and COO

$226K−13.0%Apr 8
SVRABuy

Robert N Neville · CEO

$150K+5.0%Dec 21
SVRASell

David L Lowrance · CFO

$170K−100.0%Nov 2
SVRASell

Robert N Neville · CEO

$217K−4.0%Jun 12
SVRASell

David L Lowrance · CFO

$64K−22.0%Jun 12
SVRASell

Jaakko Taneli Jouhikainen · Insider

$215K−8.0%Jun 12
SVRABuy

Yuri Pikover · Director

$34K+1.0%Apr 2
SVRASell

Robert N Neville · CEO

$323K−6.0%Feb 20
SVRASell

Jaakko Taneli Jouhikainen · Insider

$321K−11.0%Feb 20
SVRASell

David L Lowrance · CFO

$90K−23.0%Feb 20
Older filings
About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.